| O48 | In silico assessment of variation in TMB quantification across diagnostic platforms: Phase 1 of the Friends of Cancer Research Harmonization Project | David Fabrizio, PhD, Shu-Jen Chen, PhD, Mingchao Xie, PhD, Wangjuh Chen, PhD, Katie J. Quinn, PhD, Chen Zhao, PhD, Ahmet Zehir, PhD, Vincent Funari, PhD (CGMBS), Jennifer S. Dickey, PhD, Vikas Gupta, PhD, Dinesh Cyanam, PhD, Lisa M. McShane, PhD, Naiyer A. Rizvi, MD, Matthew Hellmann, MD, Mark Stewart, PhD, Diana M. Merino, PhD, Jeff Allen, PhD | Bioinformatics,Biomarkers,Immunoscore,Neoantigens,Targeted therapy,Tumor antigens |
| O49 | Imaging of tumor infiltrating T cells with an anti-CD8 minibody 89Zr-IAB22M2C in advanced solid tumors: a phase I first-in-human study | Michael S. Gordon, MD, Frank Tsai, Michael Postow, MD, Matthew Hellmann, MD, James J. Harding, MD, Ronald L. Korn, MD, Michael D. Farwell, MD, Tara C. Mitchell, Lynn M. Schuchter, MD, Martha Ziolkowska, Joseph O'Donoghue, Jason S. Lewis, Anna M. Wu, Ph.D., William Le, Ian Wilson, Wolfgang A. Weber, Jedd D. Wolchok, MD, PhD, Deepak Behera, MD, Neeta Pandit-Taskar, | Biomarkers,Clinical trial,Immune contexture,Immune monitoring,Solid tumors,T cell,Tumor infiltrating lymphocytes (TILs),Tumor microenvironment |
| O50 | Pembrolizumab in combination with chemoradiotherapy (CRT) in human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) | Steven F. Powell, MD, Mark Gitau, MD, John Reynolds, MD, Andrew Terrell, MD, Michele M. Lohr, MD, MS, Steven McGraw, MD, Ryan K. Nowak, MD, Ash Jensen, MD, Miran Blanchard, MD, Christopher D. Fischer, MD, Christie Ellison, RN, Lora Black, MPH, Paul A. Thompson, PhD, Kathryn Gold, MD, Ezra Cohen, MD, Julie Bykowski, MD, John Lee, MD, William C. Spanos, MD, | Checkpoint blockade,Chemotherapy,Clinical study,Clinical trial,Radiotherapy |
| O51 | Monalizumab in combination with cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): clinical and translational biomarker results. | Roger Cohen, Jerome Fayette, Marshall Posner, MD, Gautier Lefebvre, Jessica Bauman, MD, Sebastien Salas, Caroline Even, Dimitrios Colevas, Antonio Jimeno, MD, PhD, Esma Saada-Bouzid, MD, PhD, Barbara A. Burtness, MD, Franceline Calmels, Robert ZERBIB, MSc, Agnès Boyer-Chammard, MD, Pascale André, PhD, Tanguy Seiwert, MD | Antibody,Biomarkers,Checkpoint blockade,Clinical study,Immune monitoring,NK/NK T cell,Solid tumors,T cell,Targeted therapy,Tumor infiltrating lymphocytes (TILs) |
| O52 | Intratumoral injection of a novel oncolytic virus, Voyager V1 (VV1): completed phase 1 monotherapy in patients with refractory solid tumors | Steven F. Powell, MD, Jaime Merchan, Manish R. Patel, DO, Timothy P. Cripe, MD, PhD, James Strauss, MD, Matthew Old, MD, Rosa M. Diaz, PhD, Kah Whye Peng, PhD, Stephen J. Russell, MD, PhD, Alice S. Bexon | Biomarkers,Clinical trial,Cytokine,Immune monitoring,Regulatory T cell (Treg cell),Solid tumors,T cell |
| P706 | Effects of indoximod plus gemcitabine/nab-paclitaxel on tumor microenvironment of patients with metastatic pancreas cancer | Jiayi Yu, PhD, Gabriela R. Rossi, PhD, Devora Delman, Joey Li, BS, Ravindra Kolhe, MD, PhD, David H. Munn, MD, Nathan Bahary, MD, PhD, Nicholas Vahanian, MD, Eugene P. Kennedy, MD, FACS, Gregory L. Beatty, MD, PhD, Charles Link, Jr., MD, | Chemotherapy,Clinical study,Clinical trial,Immune monitoring,Solid tumors,Tumor microenvironment |
| P707 | Tumor mutational burden (TMB) ring study: Comparison of multiple targeted next-generation sequencing (NGS) sequencing platforms | Jeffrey Conroy, BS, Sarabjot Pabla, MSc, PhD, BS, Yirong Wang, M.S., Sean T. Glenn, PhD, Razelle Kurzrock, MD, Shumei Kato, MD, Ryosuke Okamura, Denis A. Smirnov, Brad Foulk, Traci Pawlowski, PhD, Dinesh Cyanam, PhD, Geoffrey M. Lowman, PhD, Blake Burgher, BS, RN, Jacob Hagen, Mary Nesline, MS, Antonios Papanicolau-Sengos, MD, Felicia L. Lenzo, Mark Gardner, Carl D. Morrison, MD, DVM, | Biomarkers,Checkpoint blockade,Solid tumors |
| P708 | Immunopharmacodynamic responses of Imprime PGG combined with Pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer subjects in a Phase 2 trial: Analyses of Stage 1 patients | Nadine Ottoson, BS, Adria B. Jonas, MS, Anissa S. Chan, PhD, Xiaohong Qiu, BS, Blaine Rathmann, BS, Richard Walsh, BS, Ben Harrison, MS, Mike Danielson, PhD, Kyle S. Michel, BA, Michaela Finley, Mark Uhlik, PhD, Jamie Lowe, BA, Paulette Mattson, BFA, Michele A. Gargano, MS, Michael J. Chisamore, PhD, Joanna Cox, MD, Bruno Osterwalder, MD, Jeremy R. Graff, PhD, Nandita Bose, PhD, Nadine Ottoson, BS, | Biomarkers,Checkpoint blockade,Chemokine,Clinical study,Clinical trial,Gene expression,Immune monitoring,Myeloid cells,T cell |
| P709 | Peripheral Blood TCRB Chain Convergence Predicts Response to Dendritic Cell-Based Immunotherapy in Advanced-Stage Melanoma Patients | Walter J. Storkus, PhD, Yan Lin, Lauren Miller, BS, Denise S. Topacio-Hall, BS, MA, Geoffrey M. Lowman, PhD, Timothy Looney, PhD, Lisa H. Butterfield, PhD, Jennifer L. Taylor, Ph.D., Ahmad A. Tarhini, MD, PhD, Hussein A. Tawbi, MD, PhD, John M. Kirkwood, MD, | Biomarkers,Clinical trial,Dendritic cell,Gene expression,Immune monitoring,Solid tumors,T cell,Tumor infiltrating lymphocytes (TILs),Tumor microenvironment,Vaccine |
| P710 | Phase 1/2 study of image guided intratumoral CD40 agonistic monoclonal antibody (APX005M) in combination with systemic pembrolizumab for treatment-naïve metastatic melanoma | Salah Eddine Bentebibel, Daniel H. Johnson, MD, Srisuda Lecagoonporn, PhD DPharm, Cara Haymaker, PhD, Houssein Safa, MD, Cassian Yee, MD, Rodabe N. Amaria, MD, Sapna Patel, MD, Hussein A. Tawbi, MD, PhD, Isabella C. Glitza, MD, PhD, Michael Davies, MD, PhD, Michael K. Wong, MD PhD FRCPC, Wen-Jen Hwu, MD, PhD, Patrick Hwu, MD, Willem W. Overwijk, PhD, Ovid C. Trifan, MD, PhD, Chantale Bernatchez, Adi Diab, MD, | Antibody,Antigen presenting cells,Biomarkers,Checkpoint blockade,Clinical study,Clinical trial,Costimulation,Dendritic cell,Immune monitoring,Solid tumors,T cell,Tumor microenvironment |
| P711 | HepaVac-101 first-in-man therapeutic cancer vaccine Phase I/II clinical trial for hepatocellular carcinoma patients | Luigi Buonaguro, MD, Andrea Mayer-Mokler, Roberto Accolla, Yuk T. Ma, Regina Heidenreich, Antonio Avallone, Ester Simeone, Alfred Koenigsrainer, Markus Loeffler, Cecile Gouttefangeas, PhD, Christian Flohr, Jörg Ludwig, Diego D. Alcoba, M.Sc., Ph.D., Sarah Kutscher, Maria Tagliamonte, Paolo A. Ascierto, Hans-Georg Rammensee, PhD, Bruno Sangro, Mercedes Iñarrairaegui Bastarrica, Sven Francque, MD, PhD, Luisa Vonghia, Danila Valmori, Tanguy Chaumette, Toni Weinschenk, PhD, Carsten Reinhardt, MD, PhD, Ulrike Gnad-Vogt, MD, Luigi Buonaguro, MD, Harpreet Singh-Jasuja, | Clinical trial,Solid tumors,Tumor antigens,Vaccine |
| P712 | Early phase 2 clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients demonstrating 86% CR of carcinoma in situ (CIS) | John Lee, MD, Patrick Soon-Shiong, MD, FRCS, FACS, Karim Chamie, MD, Amy Rock, PhD, Peter Rhode, PhD, | Antigen presenting cells,Clinical study,Clinical trial,Cytokine,Immune adjuvant,NK/NK T cell,Regulatory T cell (Treg cell),T cell,Tumor microenvironment,Vaccine |
| P713 | NANT Cancer Vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer | Patrick Soon-Shiong, MD, FRCS, FACS, John Lee, MD, Tara Seery, MD, Mira Kistler, MD, Arvind Shinde, Anand Annamalai, Leonard Sender, Frank Jones, PhD, Omid Jafari, MD, | Checkpoint blockade,Chemotherapy,Clinical study,Clinical trial,Cytokine,Dendritic cell,NK/NK T cell,Radiotherapy,Solid tumors,Tumor antigens |
| P714 | Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin lymphoma. | Vivek S. Radhakrishnan, MD, DM, Sameer Bakhshi, MD, Kumar Prabhash, MD, Chetan Deshmukh, MD, Shona Nag, MD, KC Lakshmaiah, MD, M Gopichand, MCh, Murali Ramachandra, PhD, Sudeep Gupta, MD, Shripad D. Banavali, MD, Divyesh Mandavia, Akhil Kumar, MD, | Adoptive immunotherapy,Checkpoint blockade,Clinical study,Clinical trial,Immune toxicity,Leukemia/Lymphoma,MDSC,Solid tumors,T cell |
| P715 | A Phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Analysis of the first stage | Matthew G. Krebs, MD PhD, Paal F. Brunsvig, MD PhD, Nuria Vinolas Segarra, Luis Paz-ares, Enric Carcereny, Enriqueta Felip, MD PhD, Manuel Dómine Gómez, MD PhD, José Trigo, MD, Edume Arriola, MD PhD, Maria Rosario Garcia Campelo, MD PhD, James Spicer, MD, PhD, Jonathan Thompson, MD MS, Konstantin Dragnev, MD, David Micklem, PhD, Robert Holt, PhD, Anthony Brown, James Lorens, PhD, Michael J. Chisamore, PhD, Matthew G. Krebs, MD PhD, | Checkpoint blockade,Clinical study,Clinical trial,Coinhibition,Solid tumors,Targe+BL:CH |
| P716 | The first clinical/translational data from the expansion cohorts of a Ph1/1b Study of IPI-549, a tumor macrophage-reprogramming small molecule, in combination with nivolumab in advanced solid tumors | Bartosz Chmielowski, MD, PhD, Ryan J. Sullivan, MD, Michael Postow, MD, Amita Patnaik, MD FRCP(C), Geoffrey Shapiro, MD, PhD, Ezra Cohen, MD, Martin Gutierrez, MD, Conor Steuer, MD, Antoni Ribas, MD, PhD, Lucy Lee, PHARMD, DABCP, FCP, Brenda O'Connell, PhD, Jeffery Kutok, MD, PhD, Jennifer Roberts, Suresh Mahabhashyam, MBBS, Marie-Louise Fjallskog, MD, Jedd D. Wolchok, MD, PhD, David Hong, MD, | Chemokine,Clinical study,Immune suppression,Monocyte/Macrophage,Myeloid cells,MDSC,Solid tumors,Targeted therapy,Tumor microenvironment |
| P717 | Initial report of intratumoral tavokinogene telseplasmid with pembrolizumab in advanced melanoma: an approach designed to convert PD-1 antibody progressors into responders. (NCT 03132675) | Sharron E. Gargosky, PhD, Victoria Atkinson, MD, Andrew Haydon, MBBS PhD, Phillip Parente, Tom Van Hagen, Gregory A. Daniels, MD, PhD, Pablo Fernandez-Penas, MD, PhD, Mecker Moller, Igor Puzanov, MD, MSCI, FACP, Sajeve Thomas, Robert H. Andtbacka, MD, CM, FACS, FRCSC, Clemens Krepler, MD, David A. Canton, PhD, Christopher Twitty, PhD, Sharron E. Gargosky, PhD, | Checkpoint blockade,Clinical trial,Cytokine,Immune monitoring,T cell,Tumor microenvironment |
| P718 | Profiling PD-1 blockade pharmacodynamics using a live tissue explant model of head and neck squamous cell carcinoma. | Munisha Smalley, PharmD, Steven B. Maron, MD, Manjusha Biswas, MD, Mark Lawson, BA, HTL(ACSP), Biswanath Majumder, Basavaraja Uddajjara Shanthappa, Saravanan Thiyagaragan, Kodaganur S. Gopinath, k.s. sabitha, Joseph F. Grosso, PhD, Tanguy Seiwert, MD, Aaron Goldman, | Antigen presenting cells,Biomarkers,Checkpoint blockade,Clinical study,Gene expression,Immune contexture,Immune monitoring,Immune tolerance,Inflammation,Myeloid cells,MDSC,Regulatory T cell (Treg cell),Solid tumors,T cell,T cell lineages,Tumor infiltrating lymphocytes (TILs),Tumor antigens,Tumor evasion,Tumor microenvironment |
| P719 | A SITC-sponsored randomized clinical trial to determine criteria to guide clinicians on when to stop immunotherapy through a community-driven data repository, leveraging the SITC community | Jennifer L. Guerriero, PhD, Jessica Thaxton, PhD, MSCR, Todd Bartkowiak, Esha Sachdev, MD, Jiajia Zhang, MD, MPH, Abdul Rafeh Naqash, MD, Rania H. Younis, B.D.S., M.D.S., Ph.D., Sarah E. Church, Maria E. Rodriguez-Ruiz, MD, PhD, Rosa Nguyen, Kit Fuhrman, PhD, Sabrina Kaczanowska, Abigail E. Overacre-Delgoffe, PhD, Dipti Thakkar, PhD, Yinghong Wang, MD, PhD, Aideen E. Ryan, PhD, Claire A. Margolis, MS, Rachel Howard, Daniel J. Olson, MD, Michal Sheffer, PhD, Kristin G. Anderson, PhD, Yuanquan Yang, MD, PhD, Namrata S. Chandhok, Vaia Florou, MD, Sangeetha M. Reddy, MD, MSci, David H. Aggen, MD, PhD, Ravi Patel, MD, PhD, Presenting Author - Thomas U. Marron, MD PhD, | Bioinformatics,Biomarkers,Checkpoint blockade,Clinical trial,Immune monitoring,Immune suppression,Immune tolerance,Immunoscore,Metabolism,Microbiome,Proteomics,Regulatory T cell (Treg cell),Solid tumors,T cell,Tumor infiltrating lymphocytes (TILs),Tumor microenvironment,Tumor stroma |
| P720 | Regional delivery of anti-CTLA-4 to induce systemic anti-tumor immunity with limited autoimmune toxicity | Airi Harui, PhD, Airi Harui, PhD, Airi Harui, PhD, Michael D. Roth, MD, Sandra M. McLachlan, PhD, | Checkpoint blockade,Immune toxicity |
| P721 | Single-cell PSI of CD8+ TILs in melanoma shows uniquely sensitive correlation with response to anti-PD-1 therapy, where histology and serum cytokines were unable to detect significant associations | Sean G. Mackay, MBA, Brianna Flynn, MS, Kevin Morse, Patrick Paczkowski, Jonathan Chen, MS, Antonella Bacchiocchi, James R. Heath, Rong Fan, PhD, Mario Sznol, MD, Ruth Halaban, PhD, Jing Zhou, MD, PhD, | Bioinformatics,Biomarkers,Checkpoint blockade,Chemokine,Cytokine,Immune monitoring,Proteomics,Solid tumors,T cell,Tumor infiltrating lymphocytes (TILs) |
